Pangaea Oncology announced this morning for the BME Growth market the agreement reached by Pangaea and Oncopdo, a subsidiary established under the existing joint venture with the Singapore biotechnology company Invitrocue PTE, with Eurofins-Megalab for the marketing of the portfolio ONCOPDO Organoid test, together with the Pangea Liquid Biopsy tests in Spain and Portugal.
The duration of the agreement is three years, renewable biannually, and grant marketing rights to MEGALAB in the private hospital sector in the Iberian Peninsula, maintaining both PANGEAA and ONCOPDO, the possibility of marketing in the groups and clients in which it already operates.
the european group EUROFINS-MEGALAB, with more than 55,000 employees in 900 laboratories in 50 countries and an annual sales volume of more than 5.4 billion euros, is a leading international group of laboratories at a global level that offers a unique range of analytical and scientific-technical services to the industries and authorities that operate in the pharmaceutical, agri-food, environmental and consumer goods sectors.
www.estrategiasdeinversion.com